SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 574.05 |
| Enterprise Value ($M) | 358.68 |
| Book Value ($M) | 445.45 |
| Book Value / Share | 22.09 |
| Price / Book | 1.29 |
| NCAV ($M) | 366.71 |
| NCAV / Share | 18.19 |
| Price / NCAV | 1.57 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.41 |
| Return on Assets (ROA) | -0.73 |
| Return on Equity (ROE) | -0.80 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.77 |
| Current Ratio | 10.77 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 404.37 |
| Assets | 483.11 |
| Liabilities | 37.66 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 8.55 |
| Operating Income | -200.16 |
| Net Income | -182.82 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -131.76 |
| Cash from Investing | -248.49 |
| Cash from Financing | 514.32 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Soleus Capital Master Fund, L.P. | 5.00 | ||
| 13G/A | Perceptive Advisors Llc | 9.50 | 63.51 | |
| 13G/A | Point72 Asset Management, L.P. | 6.30 | -29.09 | |
| 13G/A | Cormorant Asset Management, LP | 9.08 | 94.62 | |
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 6.10 | 31.31 | |
| 13G | Morgan Stanley | 6.20 | ||
| 13G | Price T Rowe Associates Inc /md/ | 6.30 | ||
| 13G/A | Verition Fund Management LLC | 1.80 | -55.29 | |
| 13G/A | Ra Capital Management, L.p. | 4.30 | -38.33 | |
| 13G | Capital Research Global Investors | 5.60 | ||
| 13G/A | Adage Capital Management, L.P. | 4.81 | ||
| 13G/A | Vanguard Group Inc | 5.85 | 0.00 | |
| 13G | BlackRock, Inc. | 7.30 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 49,160 | 374,527 | 13.13 | |
| 97,209 | 594,734 | 16.34 | |
| 86,043 | 782,483 | 11.00 | |
| 203,705 | 938,048 | 21.72 | |
| 119,535 | 563,191 | 21.22 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PHVS – Pharvaris N.V. | PLRX – Pliant Therapeutics, Inc. |
| PMVP – PMV Pharmaceuticals, Inc. | PRLD – Prelude Therapeutics Incorporated |
| PRTA – Prothena Corporation plc |
Financial data and stock pages provided by
Fintel.io